Literature DB >> 12134947

Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.

Fuxing Tang1, Ronald T Borchardt.   

Abstract

PURPOSE: To elucidate the efflux transporter(s) responsible for restricting the permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE (AD) through Caco-2 cell monolayers.
METHODS: The cellular permeation characteristics of AD were investigated using Caco-2 cells, Madin-Darby canine kidney wild-type II cells (MDCK-WT), MDCK cells transfected with the human MDR1 gene (MDCK-MDR1), and MDCK cells transfected with the human MRP2 gene (MDCK-MRP2). These cells were grown as monolayers onto microporous membranes. The disappearance of AD from the donor side and its appearance on the receiver side were monitored by high-performance liquid chromatography. The substrate activity of AD for P-glycoprotein (P-gp) was determined using GF120918, a known P-gp specific inhibitor. The substrate activity of AD for MRP2 was determined by using cyclosporin A, a known MRP2 and P-gp inhibitor.
RESULTS: In Caco-2 cells, the ratio of the apparent permeability coefficients (Papp) of AD flux measured in the basolateral (BL) to apical (AP) direction vs. the flux in the AP-to-BL direction (Papp BL-to-AP/ Papp AP-to-BL) was 99. In the presence of 2 microM GF120918 or 25 microM cyclosporin A. the Papp BL-to-AP/Papp AP-to-BL ratio was decreased to 11. In MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells, the Papp BL-to-AP/Papp AP-to-BL ratios of AD were 4.7, 10, and 5.8, respectively. A mixture of GF120918 (2 microM) and cyclosporin A (25 microM) decreased the Papp BL-to-AP/Papp AP-to-BL ratios of AD in MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells to 1.2,1.8, and 2.3, respectively.
CONCLUSIONS: These data suggest that AD is a much better substrate for P-gp than MRP2 and that the restricted permeation of this cyclic prodrug in Caco-2 cells and in the intestinal mucosa probably is due primarily to its substrate activity for P-gp.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134947     DOI: 10.1023/a:1016144530146

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  34 in total

1.  Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-09-15       Impact factor: 15.470

2.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

Authors:  M de Bruin; K Miyake; T Litman; R Robey; S E Bates
Journal:  Cancer Lett       Date:  1999-11-15       Impact factor: 8.679

3.  The application of cell culture systems in drug discovery and development.

Authors:  R Borchardt
Journal:  J Drug Target       Date:  1995       Impact factor: 5.121

Review 4.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

Authors:  J König; A T Nies; Y Cui; I Leier; D Keppler
Journal:  Biochim Biophys Acta       Date:  1999-12-06

5.  Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker.

Authors:  A Bak; T J Siahaan; O S Gudmundsson; S Gangwar; G J Friis; R T Borchardt
Journal:  J Pept Res       Date:  1999-04

6.  Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide.

Authors:  G M Pauletti; S Gangwar; F W Okumu; T J Siahaan; V J Stella; R T Borchardt
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

7.  Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B.

Authors:  A T Nies; T Cantz; M Brom; I Leier; D Keppler
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators.

Authors:  J Hunter; M A Jepson; T Tsuruo; N L Simmons; B H Hirst
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

9.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

10.  Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.

Authors:  A Bak; O S Gudmundsson; G J Friis; T J Siahaan; R T Borchardt
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

View more
  5 in total

Review 1.  Cyclization-activated prodrugs.

Authors:  Paula Gomes; Nuno Vale; Rui Moreira
Journal:  Molecules       Date:  2007-11-12       Impact factor: 4.411

2.  A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.

Authors:  Hui Ouyang; Fuxing Tang; Teruna J Siahaan; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.

Authors:  Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 4.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  Expression of intestinal transporter genes in beagle dogs.

Authors:  Soo-Min Cho; Sung-Won Park; Na-Hyun Kim; Jin-A Park; Hee Yi; Hee-Jung Cho; Ki-Hwan Park; Ingyun Hwang; Ho-Chul Shin
Journal:  Exp Ther Med       Date:  2012-10-30       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.